TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07085104: A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease

Sponsor: Allogene Therapeutics · Phase: PHASE1 · Area: IMMUNOLOGY · Target Enrollment: 66 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$1,407,600

Rescue Site Savings

+$938,400

Unlock Full NCT07085104 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07085104 Rescue Dossier →